Lucosky Brookman LLP Successfully Represents EF Hutton in $4 Million Offering of TC Biopharm (Holdings) PLC American Depositary Shares (ADS)
Lucosky Brookman congratulates its client, EF Hutton, division of Benchmark Investments, LLC, on its successful $4 million underwritten public offering of American Depositary Shares (ADS) of TC Biopharm (Holdings) PLC (Nasdaq: TCBP; TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications. The offering consists of 10,000,000 ADSs, each ADS representing one ordinary share of the Company, at a public offering price of $0.40 per ADS, for aggregate gross proceeds of $4 million, prior to deducting underwriting discounts and commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1.5 million ADSs at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any.
Lucosky Brookman represented EF Hutton in its capacity as sole book-running manager.